SecBot SecBot
PRESS-RELEASE ·Filed Nov 13, 2026

ONCY

Oncolytics Biotech, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed3d 14h ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

The agreement provides pelareorep access to a marketed PD-1 inhibitor without upfront cost, but the study is early-stage (Phase 2, single indication) and results are at least 12-18 months away. Monitor for enrollment updates and interim data; the deal does not change Oncolytics' near-term cash runway or revenue outlook.

DirectionNeutral
Confidencemedium
Horizonmonths

Drugs in focus

ONCY drug pipeline →

pelareorep

◆ Mixed Named in this press release
Impact
Phase
Phase 2/3
Time to market
At least 3-5 years (Phase 3 just launching; no BLA/NDA filed)
Next catalyst
None dated

What to watchOncolytics is a single-asset clinical-stage biotech with no approved products. The stock trades at ~$0.92 against a mean analyst price target of ~$4.94 (~5x upside), but the company has limited cash (~$12.4M as of Q3 2025) and has tapped a $75M ATM facility, significant dilution risk. Watch for the Phase 3 pancreatic cancer trial launch (H1 2026) and any anal cancer registration updates, but do not expect a near-term binary catalyst.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.3700
T+0 close · Nov 13, 2026 · via day close
Latest settled
−8.14%
T+1 · $0.3399
Vs SPY
−6.22%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $0.3700entry
  2. T+1 · 20h ago −8.14%α −6.22% · $0.3399
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oncolytics Biotech entered a clinical supply agreement with Coherus Oncology to evaluate its oncolytic virus pelareorep in combination with Coherus' PD-1 inhibitor LOQTORZI (toripalimab) in a Phase 2 study for second-line squamous cell anal carcinoma (SCAC). The study is expected to start in Q1 2027 at a U.S. cancer center, targeting patients who have progressed on first-line chemo-immunotherapy. This is a non-dilutive supply deal with no upfront payment or milestone disclosed, providing pelareorep access to a marketed checkpoint inhibitor for a new indication with no approved second-line therapy.

Key Facts

  • Clinical supply agreement with Coherus Oncology for LOQTORZI (toripalimab-tpzi) in combination with pelareorep
  • Study targets second-line squamous cell anal carcinoma (SCAC) patients who progressed on first-line chemo-immunotherapy
  • No approved therapy exists for second-line SCAC
  • Study expected to begin Q1 2027 at a U.S. cancer center (to be named)
  • Coherus provides LOQTORZI; no financial terms (upfront, milestones, or royalties) disclosed
  • Pelareorep has Fast Track designation from FDA for colorectal, anal, and pancreatic cancer

Financial Impact

No financial terms disclosed; non-dilutive supply agreement with no stated upfront or milestone payments

research collaborationclinical pipeline

Risk Factors

  • Clinical trial may fail to show efficacy or safety, delaying or ending the SCAC program
  • No financial terms disclosed; deal does not provide funding for Oncolytics' operations
  • Study start is contingent on partnering with a U.S. cancer center; timeline may slip
  • SCAC is a small indication; even positive data may not materially impact valuation without broader HPV-associated cancer expansion

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402874

Track record

32 reports on ONCY

Performance horizon

3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 3/10 Viewing Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
  2. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
  3. Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
  4. Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
  5. Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
  6. Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
  7. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
  8. Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
  9. Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
  10. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
Showing 10 of 32

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026